Plerixafor

Hematopoietic Stem Cell Mobilizer — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Plerixafor is an ofp drug in the Hematopoietic Stem Cell Mobilizer class catalogued in DrugCentral. It was first approved by the FDA in 2008. DrugCentral lists 10 molecular targets, including CCR2, HRH3 and CXCL12. Recorded indications include Malignant lymphoma, Multiple myeloma, Peripheral Mobilization of Hematopoietic Stem Cells and Solid malignant tumours.

• Approval status: ofp (first approved 2008 by the FDA).
• Drug class: Hematopoietic Stem Cell Mobilizer.
• Molecular targets: CCR2, HRH3, CXCL12 and Cxcr4 (10 listed in DrugCentral).
• Indications: Malignant lymphoma, Multiple myeloma, Peripheral Mobilization of Hematopoietic Stem Cells and Solid malignant tumours.
• ATC code: L03AX16 (Other immunostimulants).
• Molecular formula: C28H54N8; molecular weight 502.80 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (4)

• Malignant lymphoma
• Multiple myeloma
• Peripheral Mobilization of Hematopoietic Stem Cells
• Solid malignant tumours

Contraindications (7)

• Breastfeeding (mother)
• Impaired renal function disorder
• Leukemia, disease
• Leukocytosis
• Nontraumatic splenic rupture
• Pregnancy, function
• Thrombocytopenic disorder

Mechanism & targets

• Established pharmacologic class: Hematopoietic Stem Cell Mobilizer

Molecular targets (10)

Target	Gene	Action	Activity
C-C chemokine receptor type 2	CCR2	unknown	IC50 10.40
Histamine H3 receptor	HRH3	unknown	Ki 8.56
Stromal cell-derived factor 1	CXCL12	unknown	IC50 8.24
C-X-C chemokine receptor type 4	Cxcr4	unknown	IC50 6.97
Atypical chemokine receptor 3	ACKR3	agonist	EC50 6.85
C-C chemokine receptor type 4	CCR4	antagonist	IC50 6.19
Muscarinic acetylcholine receptor M1	CHRM1	unknown	Ki 6.09
C-X-C chemokine receptor type 4	CXCR4	partial agonist	Ki 6.05
Muscarinic acetylcholine receptor M2	CHRM2	unknown	Ki 5.99
Alpha-2C adrenergic receptor	ADRA2C	unknown	Ki 5.75

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2009-07-30	EMA	—	Sanofi B.V.
2008-12-15	FDA	—	GENZYME	Yes

ATC classification

ATC code	Therapeutic hierarchy
L03AX16	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSTIMULANTS › IMMUNOSTIMULANTS › Other immunostimulants

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Febrile neutropenia	210.3
Mucosal inflammation	146.0
Plasma cell myeloma	140.4
Blood stem cell harvest failure	122.1
Venoocclusive liver disease	97.9
Thrombocytopenia	87.4
Engraftment syndrome	61.2
Brain teratoma	59.3
Therapy non-responder	51.8
Engraft failure	48.2
Escherichia infection	44.1
Bone pain	42.8

Chemical structure

• Molecular formula: C₂₈H₅₄N₈
• Molecular weight: 502.80 g/mol
• CAS number: —
• InChIKey: YIQPUIGJQJDJOS-UHFFFAOYSA-N
• PubChem CID: 65015

C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Plerixafor used for?

DrugCentral lists the following indications for Plerixafor: Malignant lymphoma, Multiple myeloma, Peripheral Mobilization of Hematopoietic Stem Cells and Solid malignant tumours.

How does Plerixafor work?

Its molecular targets in DrugCentral include CCR2, HRH3, CXCL12 and Cxcr4.

When was Plerixafor first approved?

Plerixafor was first approved by the FDA in 2008.

What drug class does Plerixafor belong to?

Plerixafor is in the Hematopoietic Stem Cell Mobilizer class.

What is the chemical formula of Plerixafor?

Plerixafor has the molecular formula C28H54N8 and a molecular weight of 502.80 g/mol.

Sources

• DrugCentral drug card 4410 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL18442 — compound record and bioactivity
• PubChem CID 65015 — chemical identifiers
• DrugBank DB06809 — drug record
• FDA UNII S915P5499N — substance identity
• DailyMed: FDA labels for Plerixafor — current prescribing information (label search)
• UniProt P41597 (CCR2) — target protein
• UniProt Q9Y5N1 (HRH3) — target protein
• UniProt P48061 (CXCL12) — target protein
• UniProt P25106 (ACKR3) — target protein
• UniProt P51679 (CCR4) — target protein
• UniProt P11229 (CHRM1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.